Exer Labs, Inc

Form 483 issued October 24, 2024 · Denver, Colorado

Inspection
Oct 17 – Oct 24, 2024
Investigator
Matthew M. Vernon
Observations
10
Pages
7
FEI number
3020929899

In short: On October 24, 2024, FDA issued a Form 483 with 10 observations to Exer Labs, Inc in Denver, Colorado (FEI 3020929899) after an inspection that ran Oct 17 – Oct 24, 2024. The investigator was Matthew M. Vernon. Most observations concern management controls and cAPA; the most-cited regulation is 21 CFR 820.20 (management responsibility).

At a glance

Management controls and capa account for 7 of 10 observations.

Management controls4
CAPA3
Production & process controls2
Design controls1

What FDA observed

Preview: the opening words of each observation
  1. 01

    Procedures for design control…

  2. 02

    Procedures for collective and preventive action have…

  3. 03

    Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit…

  4. 04

    Written MDR procedures have not been…

6 more observations

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Exer Labs, Inc?

FDA listed 10 observations on this Form 483, mostly about management controls, cAPA and production & process controls. The most-cited regulation is 21 CFR 820.20 (management responsibility). The opening words of each observation are shown on this page.

Who inspected Exer Labs, Inc?

Matthew M. Vernon is named on this Form 483, for the inspection of Oct 17 – Oct 24, 2024. Each investigator has a profile showing what they cite most.

When was Exer Labs, Inc inspected by FDA?

The inspection ran Oct 17 – Oct 24, 2024, and the Form 483 is dated October 24, 2024.

How do I get the full Form 483 for Exer Labs, Inc?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free